Document Type : Original Article
Department of Biochemistry, Faculty of Veterinary Medicine, Benha University.
Department of Zoology, Faculty of Science, Tanta University
The present study aimed to evaluate the positive effects of amygdalin against mammalian tumors in-vivo. Twenty female albino mice, 4-6 weeks old age, were used, equally divided into four groups: group I (control) received no drugs; group II (carcinogenic group) received oral 7,12-dimethylbenz[a]anthracene (DMBA) (50 mg/kg once a weak) dissolved in sesame oil for 4 weeks; group III (therapeutic group) received oral Amygdalin (0.6 mg/kg/day) dissolved in 100% corn oil for 4 weeks after DMBA-induced tumor as in group II; group IV (protective group) received Amygdalin as in group III prior DMBA administration. The results showed that DMBA-induced mammalian tumors caused a significant increase in serum bilirubin (total & direct). Still, a substantial decrease in serum albumin as a hepatic function was recorded. Serum uric acid as a kidney marker revealed a significant increase. In addition, mammalian tissue L-malondialdehyde (L-MDA) concentration showed substantial growth and a considerable decrease in mammalian tissue total antioxidant capacity (TAC) concentration compared with the control group. However, the administration of Amygdalin was able to mitigate DMBA-induced mammalian tumors through decreasing total and direct bilirubin, uric acid concentration, as well as L-MDA concentration, along with a significant increase of TAC concentration in mammalian tissue. Additionally, hematological parameters of Amygdalin-administrated mice showed a substantial increase compared to mice with mammalian tumors induced by DMBA. Thus, it can be concluded that Amygdalin may successfully protect mammary tumors.